VI-1121 for the Treatment Alzheimer's Disease
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | August 2011 |
| End Date: | September 2013 |
| Contact: | Medpace Recruitment, Center |
| Email: | recruitment@medpace.com |
| Phone: | 1-866-872-2349 |
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and
effective as a daily treatment for Alzheimer's disease that is worsening despite current
treatment.
Inclusion Criteria:
- clinical diagnosis of Alzheimer's disease
- CT or MRI within 2 years prior to study
- stable dose of current Alzheimer's treatment for at least 3 months
Exclusion Criteria:
- advanced, severe, progressive or unstable disease
- history of cerebrovascular disease or myocardial infarction within 6 months
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials